Vogt–Koyanagi–Harada disease‐like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma

Fusumae, Takayuki; Maekawa, Takeo; Komine, Mayumi; Murata, Satoru; Inoda, Satoru; Takahashi, Ryota; Kawashima, Hidetoshi; Ohtsuki, Mamitaro

doi:10.1111/1346-8138.14200

Cited by 16 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From 2011 to 2020, 93 cases of uveitis were reported in 55 articles [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 ,…”

Section: Resultsmentioning

confidence: 99%

Clinical Manifestations, Diagnosis, Treatment and Prognosis of Uveitis Induced by Anticancer Drugs: A Review of Literature

Yang

Bai

et al. 2022

Brain Sciences

View full text Add to dashboard Cite

There are increasing reports that anticancer drugs, especially immunotherapy and specific targeted therapy, can cause uveitis, but it is not fully understood whether the clinical features of this drug-induced uveitis differ from those of other types of uveitis and whether there are differences between these drugs. We retrospectively reviewed the published cases and case series in PubMed, Embase, Web of Science, and Cochrane from January 2011 to October 2020. We analysed the data, including patients’ basic information, medications used, duration of use, time to onset, clinical manifestations, diagnosis, treatment, and prognosis of uveitis. We focused on the differences in uveitis caused by immunotherapy and specific targeted therapy. Altogether 93 cases (43 men, 48 women, and 2 cases whose gender was not mentioned) reported in 55 articles were included in this study. The average age was 59.6 ± 13.5 years. Eighty percent of the patients had bilateral involvement. Sixty cases were caused by immunotherapy (64.5%), and twenty-six were caused by specific targeted therapy (27.9%). No significant difference was found in the mean time from treatment to onset between the two groups. Anticancer drug-induced uveitis can involve all parts of the uvea from anterior to posterior, manifested as anterior chamber flare, anterior chamber cells, papillitis, macular oedema, subretinal fluid, and choroidal effusion. Anterior uveitis (24 cases, 40.0%) was more common in immunotherapy, and intermediate uveitis (8 cases, 30.8%) was more common in specific targeted therapy. The mean LogMAR visual acuity in specific targeted therapy at presentation was lower than in immunotherapy, but it was not statistically significant. Corticosteroid therapy can effectively control uveitis induced by anticancer drugs. However, the survival prognosis was poor. Among the 19 patients with reported cancer prognosis, seven (36.8%) had no cancer progression, eight (42.1%) had further metastases, and four (21.0%) died of cancer. In conclusion, uveitis caused by anticancer drugs involves both eyes and manifests as various types of uveitis. Patients with specific targeted therapy are more likely to have intermediate uveitis and low vision, and immunotherapy patients are more likely to have anterior uveitis. Corticosteroids are effective against uveitis caused by anticancer drugs.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical Manifestations, Diagnosis, Treatment and Prognosis of Uveitis Induced by Anticancer Drugs: A Review of Literature

Yang

Bai

et al. 2022

Brain Sciences

View full text Add to dashboard Cite

show abstract

“…It is a systemic inflammatory disorder combining a bilateral chronic granulomatous panuveitis with central nervous system, auditory and integumentary (alopecia, vitiligo, poliosis) manifestations [40]. In the literature, few case-reports have also reported VKH or VKH-like syndrome induced by ICI (nivolumab, pembrolizumab or ipilimumab) or by protein kinase inhibitors (vemurafenib, encorafenib, binimetinib) [41][42][43][44][45][46][47], although the drug-induced form of VKH syndrome sometimes lacked the neurological, auditory or cutaneous symptoms [46,47]. Regarding the ocular symptoms, patients presented either early or late manifestations of VKH syndrome [42] and usually improved following steroids and discontinuation of immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database

Anquetil

Salem

Lebrun‐Vignes

et al. 2020

Journal of Autoimmunity

View full text Add to dashboard Cite

“…Anterior uveitis is the most common side-effect, but Vogt-Koyanagi-Harada-like uveitis and panuveitis are less commonly reported. [473][474][475][476][477][478] Acute exudative paraneoplastic polymorphous vitelliform maculopathy after starting vemurafenib in a patient already on pembrolizumab was reported in a single case report. 479…”

Section: Symptomsmentioning

confidence: 99%

The Impact of Systemic Medications on Retinal Function

Somisetty

Santina

Sarraf

et al. 2023

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

This study will provide a thorough review of systemic (and select intravitreal) medications, along with illicit drugs that are capable of causing various patterns of retinal toxicity. The diagnosis is established by taking a thorough medication and drug history, and then by pattern recognition of the clinical retinal changes and multimodal imaging features. Examples of all of these types of toxicity will be thoroughly reviewed, including agents that cause retinal pigment epithelial disruption (hydroxychloroquine, thioridazine, pentosan polysulfate sodium, dideoxyinosine), retinal vascular occlusion (quinine, oral contraceptives), cystoid macular edema/retinal edema (nicotinic acid, sulfa-containing medications, taxels, glitazones), crystalline deposition (tamoxifen, canthaxanthin, methoxyflurane), uveitis, miscellaneous, and subjective visual symptoms (digoxin, sildenafil). The impact of newer chemotherapeutics and immunotherapeutics (tyrosine kinase inhibitor, mitogen-activated protein kinase kinase, checkpoint, anaplastic lymphoma kinase, extracellular signal-regulated kinase inhibitors, and others), will also be thoroughly reviewed. The mechanism of action will be explored in detail when known. When applicable, preventive measures will be discussed, and treatment will be reviewed. Illicit drugs (cannabinoids, cocaine, heroin, methamphetamine, alkyl nitrite), will also be reviewed in terms of the potential impact on retinal function.

show abstract

Vogt–Koyanagi–Harada disease‐like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma

Cited by 16 publications

References 5 publications

Clinical Manifestations, Diagnosis, Treatment and Prognosis of Uveitis Induced by Anticancer Drugs: A Review of Literature

Clinical Manifestations, Diagnosis, Treatment and Prognosis of Uveitis Induced by Anticancer Drugs: A Review of Literature

Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database

The Impact of Systemic Medications on Retinal Function

Contact Info

Product

Resources

About